Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 5;26(7):e1110–e1124. doi: 10.1002/onco.13797

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© AlphaMed Press; the data published online to support this summary are the property of the authors.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Antitumor efficacy of combining radiotherapy and SHR‐1210. (A): Treatment exposure and response duration. The length of each bar represents the time to the last radiographic assessment according to RECIST version 1.1. Clinical and pathological features (smoking status, drinking history, clinical disease stage, and pathological test for residual tumor cells after 40 Gy) are shown for each patient (per RECIST version 1.1 by investigator review). (B): Overall survival. (C): Progression‐free survival. (D): Local recurrence–free survival. (E): Distant metastasis–free survival. Abbreviations: DMFS, distant metastasis–free survival; LRFS, local recurrence–free survival; OS, overall survival; PD‐L1, programmed cell death ligand 1; PFS, progression‐free survival; Pt, patient.